Institute for Diabetes and Cancer (IDC), Helmholtz Center Munich, Neuherberg, Germany.
Joint Heidelberg-Institute for Diabetes and Cancer (IDC), Inner Medicine 1, Heidelberg University Hospital, Heidelberg, Germany.
FASEB J. 2019 May;33(5):5924-5941. doi: 10.1096/fj.201801385RR. Epub 2019 Feb 11.
The glucocorticoid receptor (GR) represents the crucial molecular mediator of key endocrine, glucocorticoid hormone-dependent regulatory circuits, including control of glucose, protein, and lipid homeostasis. Consequently, aberrant glucocorticoid signaling is linked to severe metabolic disorders, including insulin resistance, obesity, and hyperglycemia, all of which also appear upon chronic glucocorticoid therapy for the treatment of inflammatory conditions. Of note, long-term glucocorticoid exposure under these therapeutic conditions typically induces glucocorticoid resistance, requiring higher doses and consequently triggering more severe metabolic phenotypes. However, the molecular basis of acquired glucocorticoid resistance remains unknown. In a screen of differential microRNA expression during glucocorticoid-dependent adipogenic differentiation of human multipotent adipose stem cells, we identified microRNA 29a (miR-29a) as one of the most down-regulated transcripts. Overexpression of miR-29a impaired adipogenesis. We found that miR-29a represses GR in human adipogenesis by directly targeting its mRNA, and downstream analyses revealed that GR mediates most of miR-29a's anti-adipogenic effects. Conversely, miR-29a expression depends on GR activation, creating a novel miR-29-driven feedback loop. miR-29a and GR expression were inversely correlated both in murine adipose tissue and in adipose tissue samples obtained from human patients. In the latter, miR-29a levels were additionally strongly negatively correlated with body mass index and adipocyte size. Importantly, inhibition of miR-29 in mice partially rescued the down-regulation of GR during dexamethasone treatment. We discovered that, in addition to modulating GR function under physiologic conditions, pharmacologic glucocorticoid application in inflammatory disease also induced miR-29a expression, correlating with reduced GR levels. This effect was abolished in mice with impaired GR function. In summary, we uncovered a novel GR-miR-29a negative feedback loop conserved between mice and humans, in health and disease. For the first time, we elucidate a microRNA-related mechanism that might contribute to GR dysregulation and resistance in peripheral tissues.-Glantschnig, C., Koenen, M., Gil-Lozano, M., Karbiener, M., Pickrahn, I., Williams-Dautovich, J., Patel, R., Cummins, C. L., Giroud, M., Hartleben, G., Vogl, E., Blüher, M., Tuckermann, J., Uhlenhaut, H., Herzig, S., Scheideler, M. A miR-29a-driven negative feedback loop regulates peripheral glucocorticoid receptor signaling.
糖皮质激素受体 (GR) 是关键内分泌、糖皮质激素依赖性调节回路的关键分子介体,包括控制葡萄糖、蛋白质和脂质的稳态。因此,异常的糖皮质激素信号与严重的代谢紊乱有关,包括胰岛素抵抗、肥胖和高血糖,所有这些在炎症条件下接受长期糖皮质激素治疗时也会出现。值得注意的是,在这些治疗条件下,长期暴露于糖皮质激素通常会导致糖皮质激素抵抗,需要更高剂量,从而引发更严重的代谢表型。然而,获得性糖皮质激素抵抗的分子基础仍不清楚。在人多能脂肪干细胞中糖皮质激素依赖性脂肪生成分化过程中差异 microRNA 表达的筛选中,我们发现 microRNA 29a (miR-29a) 是下调最多的转录物之一。miR-29a 的过表达会损害脂肪生成。我们发现,miR-29a 通过直接靶向其 mRNA 抑制人类脂肪生成中的 GR,下游分析表明 GR 介导了 miR-29a 的大部分抗脂肪生成作用。相反,miR-29a 的表达依赖于 GR 的激活,形成了一个新的 miR-29a 驱动的反馈环。miR-29a 和 GR 的表达在小鼠脂肪组织和人类患者的脂肪组织样本中呈负相关。在后一种情况下,miR-29a 水平与体重指数和脂肪细胞大小呈强烈负相关。重要的是,在小鼠中抑制 miR-29a 可部分挽救地塞米松治疗期间 GR 的下调。我们发现,除了在生理条件下调节 GR 功能外,炎症性疾病中的药物性糖皮质激素应用也诱导了 miR-29a 的表达,与 GR 水平降低相关。在 GR 功能受损的小鼠中,这种作用被消除。总之,我们在健康和疾病状态下,在小鼠和人类之间发现了一个新的 GR-miR-29a 负反馈回路。我们首次阐明了一种可能导致外周组织中 GR 失调和抵抗的 microRNA 相关机制。-Glantschnig, C., Koenen, M., Gil-Lozano, M., Karbiener, M., Pickrahn, I., Williams-Dautovich, J., Patel, R., Cummins, C. L., Giroud, M., Hartleben, G., Vogl, E., Blüher, M., Tuckermann, J., Uhlenhaut, H., Herzig, S., Scheideler, M. A miR-29a-driven negative feedback loop regulates peripheral glucocorticoid receptor signaling.